Dianabol vs Ezetimibe
Well Studied vs FDA Approved
avoid Mechanism-based · 64% Both Dianabol and Ezetimibe carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Dianabol Ezetimibe
Weight 300.44 Da 409.43 Da
Half-life ~4-6 hours ~22 hours
Type 17-alpha-alkylated anabolic steroid (C20H28O2) Azetidinone (C24H21F2NO3)
Key Benefits
Dianabol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Significant strength gains within the first 1-2 weeks
03 Enhanced nitrogen retention and protein synthesis
04 Improved glycogenolysis and muscular endurance
05 Pronounced muscle fullness and pumps from increased intracellular water and glycogen
06 Effective oral kickstart while waiting for injectable compounds to saturate
07 One of the fastest-acting anabolic compounds available
Ezetimibe
01 Reduces LDL cholesterol by 15-20% as monotherapy
02 Complementary mechanism to statins allows additive LDL reduction of 25% when combined
03 Minimal hepatotoxicity, making it suitable alongside hepatotoxic oral AAS
04 Simple once-daily dosing with no titration required
05 No significant impact on CoQ10 levels (unlike statins)
06 Well tolerated with a side effect profile comparable to placebo in clinical trials
07 Proven cardiovascular outcome benefit when added to statin therapy (IMPROVE-IT trial)
08 Helps manage the severe lipid disruption caused by oral steroids like Anavar and Winstrol
Side Effects
Dianabol
Significant water retention and bloating (estrogen-mediated)
Elevated blood pressure from fluid retention and increased red blood cell mass
Liver stress with elevated ALT/AST enzymes (dose and duration dependent)
Back pumps (painful lower back cramping during exercise)
Increased appetite
Oily skin and acne
Suppression of endogenous testosterone production (HPTA suppression)
Mild mood changes (increased aggression, irritability, or euphoria)
Ezetimibe
Gastrointestinal discomfort (diarrhea, abdominal pain) - mild and infrequent, reported at similar rates to placebo
Upper respiratory tract infection (reported in clinical trials but not clearly drug-related)
Fatigue and headache (uncommon, typically transient)
Contraindications
Pre-existing liver disease or impaired hepatic function
Active or history of hormone-sensitive cancers (prostate, breast)
Uncontrolled hypertension or significant cardiovascular disease
Elevated hematocrit (above 54%) at baseline
Concurrent use of other hepatotoxic oral steroids (do not stack C17-aa orals)
Pregnancy or potential exposure to pregnant women
Heavy alcohol use (compounded hepatotoxicity risk)
Cholestatic liver conditions or history of drug-induced liver injury
Known hypersensitivity to ezetimibe or any component of the formulation
Active liver disease or unexplained persistent elevations in hepatic transaminases (when combined with a statin)
Pregnancy and breastfeeding (when used in combination with a statin)
Research Evidence
Dianabol Ezetimibe
Status Well Studied FDA Approved
References 5 studies 5 studies
Latest 2017 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.